Regenesance B.V. is developing mAbs against complement 6 that may halt nerve damage and provide a better safety profile than standard of care for the orphan neurological disease myasthenia gravis. The mAbs are in lead optimization and are expected to enter the clinic in 18 months.

Myasthenia gravis is an autoimmune disorder characterized by a loss of signaling between nerve and muscle cells that leads to muscle weakness. The disease can be life threatening, as muscle weakness in the diaphragm can lead to breathing difficulty and the need for respiratory support.